Employers adapt healthcare strategies amid rising costs, focusing on specialty drugs and chronic conditions to enhance ...

Data quality issues and increased rates of claim denials provide opportunities for artificial intelligence to make ...

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

A large percentage of patients starting a medication take expensive brand-name products instead of biosimilars, even as health plans and PBMs work on converting existing brand-name prescriptions to ...

New prescriptions weren’t needed because Selarsdi (ustekinumab-aekn) and Pyzchiva (ustekinumab-ttwe) interchangeable with Stelara (ustekinumab) ...

Scripius removed Stelara (ustekinumab) from its large employer formulary and replaced it with Pyzchiva (ustekinumab-ttwe) and Selarsdi (ustekinumab-aekn) ...

Rather than broadly recommend COVID-19 shots, the advisory committee recommends making it an individual decision guided by shared decision-making with a healthcare professional.

Opzelura gains FDA approval as the first topical JAK inhibitor for children with atopic dermatitis, offering a steroid-free treatment option.

On the second day of its meeting, the Advisory Committee on Immunization Practices (ACIP) postponed a decision on giving hepatitis B vaccines at birth and revoted against coverage of the combined MMRV ...

The Advisory Committee on Immunization Practices pulled back its recommendation concerning a shot that combines the measles, ...

The researchers gauged verbal communication by analyzing how the individuals in the study narrated a story based on six cartoon images.